Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q1 EPS by 174c

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) reported Q1 EPS of ($1.75), $1.74 worse than the analyst estimate of ($0.01). Revenue for the quarter came in at $88.64 million versus the consensus estimate of $95.87 million.

For earnings history and earnings-related data on Amylyx Pharmaceuticals, Inc. (AMLX) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• Piper Sandler Upgrades Halliburton (HAL) to Overweight
• Light & Wonder to report Q2 results Aug. 4, reaffirms FY26 outlook